Research Topics


EPAR Technical Report #354
Publication Date: 11/29/2018
Type: Research Brief

Precise agricultural statistics are necessary to track productivity and design sound agricultural policies. Yet, in settings where intercropping is prevalent, even crop yield can be challenging to measure. In a systematic survey of the literature on crop yield in low-income settings, we find that scholars specify how they estimate the yield denominator in under 10% of cases. Using household survey data from Tanzania, we consider four alternative methods of allocating land area on plots that contain multiple crops, and explore the implications of this measurement decision for analyses of maize and rice yield. We find that 64% of cultivated plots contain more than one crop, and average yield estimates vary with different methods of calculating area planted. This pattern is more pronounced for maize, which is more likely than rice to share a plot with other crops. The choice among area methods influences which of these two staple crops is found to be more calorie-productive per ha, as well as the extent to which fertilizer is expected to be profitable for maize production. Given that construction decisions can influence the results of analysis, we conclude that the literature would benefit from greater clarity regarding how yield is measured across studies.

EPAR Technical Report #346
Publication Date: 04/23/2018
Type: Literature Review

The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.

EPAR Research Brief #360
Publication Date: 02/05/2018
Type: Research Brief

In this brief, we report on measures of economic growth, poverty and agricultural activity in Ethiopia. For each category of measure, we first describe different measurement approaches and present available time series data on selected indicators. We then use data from the sources listed below to discuss associations within and between these categories between 1994 and 2017.